Moderna's Patent Revoked by the European Patent Office (EPO) due to BioNTech Vaccine Dispute
Shots:
- The European Patent Office declared that Moderna's mRNA patent was invalid. This gave BioNTech and its partner Pfizer the upper hand in the patent battle between the two developers of coronavirus vaccines
- Due to dissatisfaction with the verdict, Moderna intends to seek an appeal, while Moderna has filed lawsuits against BioNTech in Germany and other nations, claiming that the latter duplicated mRNA technology that Moderna had copyrighted before the 2019 emergence of COVID-19
- The announcement caused shares of Moderna to drop 2.3% in premarket trading on Wall Street
Ref: Reuters | Image: BioNTech
Related News:- Biotheus Collaborates with BioNTech for the Development and Commercialization of PM8002 to Treat Multiple Solid Tumor Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
